Progyny, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Progyny, Inc. (PGNY) reported Net Income (Loss) Available to Common Stockholders, Diluted of $28.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-07
- Progyny, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $28.05M, a 63.93% increase year-over-year.
- Progyny, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $24.23M, a 60.91% increase year-over-year.
- Progyny, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $12.48M, a 18.54% increase year-over-year.
- Progyny, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $13.86M, a 33.04% increase year-over-year.
- Progyny, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was $58.52M, a 7.70% increase from fiscal 2024.
- Progyny, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was $54.34M, a 12.41% decline from fiscal 2023.
- Progyny, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was $62.04M, a 104.35% increase from fiscal 2022.
- Progyny, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was $30.36M, a 53.84% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.05M 10-Q · filed 2026-08-07 | $52.28M 10-Q · filed 2026-08-07 | $64.77M derived: sum of 3 quarters · filed 2026-08-07 | $78.63M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2026-03-31 | $24.23M 10-Q · filed 2026-05-08 | $36.72M derived: sum of 2 quarters · filed 2026-05-08 | $50.58M derived: sum of 3 quarters · filed 2026-05-08 | $67.69M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-12-31 | $12.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $26.35M derived: sum of 2 quarters · filed 2026-02-27 | $43.46M derived: sum of 3 quarters · filed 2026-08-07 | $58.52M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $13.86M 10-Q · filed 2025-11-07 | $30.98M derived: sum of 2 quarters · filed 2026-08-07 | $46.03M 10-Q · filed 2025-11-07 | $56.57M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-06-30 | $17.11M 10-Q · filed 2026-08-07 | $32.17M 10-Q · filed 2026-08-07 | $42.70M derived: sum of 3 quarters · filed 2026-08-07 | $53.12M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-03-31 | $15.06M 10-Q · filed 2026-05-08 | $25.59M derived: sum of 2 quarters · filed 2026-05-08 | $36.01M derived: sum of 3 quarters · filed 2026-05-08 | $52.50M derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $10.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $20.95M derived: sum of 2 quarters · filed 2026-02-27 | $37.44M derived: sum of 3 quarters · filed 2026-02-27 | $54.34M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $10.42M 10-Q · filed 2025-11-07 | $26.91M derived: sum of 2 quarters · filed 2025-11-07 | $43.80M 10-Q · filed 2025-11-07 | $57.27M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2024-06-30 | $16.48M 10-Q · filed 2025-08-08 | $33.38M 10-Q · filed 2025-08-08 | $46.85M derived: sum of 3 quarters · filed 2026-02-27 | $62.75M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2024-03-31 | $16.90M 10-Q · filed 2025-05-09 | $30.37M derived: sum of 2 quarters · filed 2026-02-27 | $46.27M derived: sum of 3 quarters · filed 2026-02-27 | $61.26M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2023-12-31 | $13.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $29.37M derived: sum of 2 quarters · filed 2026-02-27 | $44.36M derived: sum of 3 quarters · filed 2026-02-27 | $62.04M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $15.90M 10-Q · filed 2024-11-12 | $30.89M derived: sum of 2 quarters · filed 2024-11-12 | $48.57M 10-Q · filed 2024-11-12 | $51.98M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-06-30 | $14.99M 10-Q · filed 2024-08-07 | $32.67M 10-Q · filed 2024-08-07 | $36.08M derived: sum of 3 quarters · filed 2025-03-03 | $49.29M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-03-31 | $17.68M 10-Q · filed 2024-05-10 | $21.09M derived: sum of 2 quarters · filed 2025-03-03 | $34.30M derived: sum of 3 quarters · filed 2025-03-03 | $43.06M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2022-12-31 | $3.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $16.62M derived: sum of 2 quarters · filed 2025-03-03 | $25.39M derived: sum of 3 quarters · filed 2025-03-03 | $30.36M 10-K · filed 2025-03-03 | |||
| 2022-09-30 | $13.21M 10-Q · filed 2023-11-08 | $21.98M derived: sum of 2 quarters · filed 2023-11-08 | $26.95M 10-Q · filed 2023-11-08 | $42.03M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-06-30 | $8.77M 10-Q · filed 2023-08-04 | $13.74M 10-Q · filed 2023-08-04 | $28.82M derived: sum of 3 quarters · filed 2024-02-29 | $45.62M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-03-31 | $4.97M 10-Q · filed 2023-05-09 | $20.05M derived: sum of 2 quarters · filed 2024-02-29 | $36.85M derived: sum of 3 quarters · filed 2024-02-29 | $55.57M derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2021-12-31 | $15.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $31.88M derived: sum of 2 quarters · filed 2024-02-29 | $50.60M derived: sum of 3 quarters · filed 2024-02-29 | $65.77M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $16.80M 10-Q · filed 2022-11-04 | $35.52M derived: sum of 2 quarters · filed 2022-11-04 | $50.69M 10-Q · filed 2022-11-04 | $89.76M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | $18.73M 10-Q · filed 2022-08-05 | $33.89M 10-Q · filed 2022-08-05 | $72.97M derived: sum of 3 quarters · filed 2023-03-01 | $77.79M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $15.17M 10-Q · filed 2022-05-06 | $54.24M derived: sum of 2 quarters · filed 2023-03-01 | $59.06M derived: sum of 3 quarters · filed 2023-03-01 | $58.00M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | $39.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $43.89M derived: sum of 2 quarters · filed 2023-03-01 | $42.83M derived: sum of 3 quarters · filed 2023-03-01 | $46.46M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $4.82M 10-Q · filed 2021-11-08 | $5.36M 10-Q · filed 2020-11-06 | $3.76M derived: sum of 2 quarters · filed 2021-11-08 | $7.39M 10-Q · filed 2021-11-08 | $7.60M 10-Q · filed 2020-11-06 | $2.99M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | -$1.06M 10-Q · filed 2021-08-06 | -$1.81M 10-Q · filed 2020-08-07 | $2.56M 10-Q · filed 2021-08-06 | $2.25M 10-Q · filed 2020-08-07 | -$1.83M derived: sum of 3 quarters · filed 2022-03-01 | -$10.04M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $3.63M 10-Q · filed 2021-05-07 | $4.06M 10-Q · filed 2020-05-14 | -$771.00K derived: sum of 2 quarters · filed 2022-03-01 | -$8.98M derived: sum of 3 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$12.61M derived: sum of 2 quarters · filed 2022-03-01 | -$8.57M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | -$8.21M 10-Q · filed 2020-11-06 | -$4.17M 10-Q · filed 2020-11-06 | |||||
| 2019-03-31 | $79.00K 10-Q · filed 2020-05-14 | -$1.50M derived: sum of 2 quarters · filed 2021-03-01 | -$2.64M derived: sum of 3 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | -$1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$2.72M derived: sum of 2 quarters · filed 2021-03-01 | -$5.54M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | -$1.14M 10-Q · filed 2019-12-06 | -$3.96M 10-Q · filed 2019-12-06 | |||||
| 2017-12-31 | -$13.47M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |